Online HCP community allows HCPs and researchers access to the latest breakthroughs in medicine and life sciences research.
H1, has launched H1 Connect,1 the former Faculty Opinions, which it acquired in February 2022.2 Users across Life Sciences, Academic Medical Institutions, Research organizations and more access insights from H1 Connect to drive their respective fields forward.
The re-branded initiative includes the expansion of clinical trial and medical research evaluations by leading experts, as well as a bolstered community, to address the following pain points for HCPs:
With input from global Key Opinion Leaders (KOLs), H1 Connect is intended to provide HCPs with quick-to-read insights and commentary; knowledge facilitation and exchange; and collaboration among the global healthcare community.
References:
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
Fake Weight Loss Drugs: Growing Threat to Consumer Health
October 25th 2024In this episode of the Pharmaceutical Executive podcast, UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, discuss the issue of counterfeit weight loss drugs, the potential health risks associated with them, increasing access to legitimate weight loss medications and more.